equine influenza (live recombinant) and tetanus vaccine

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 03/09/2021

Authorisation details

Product details
Agency product number
Active substance
Clostridium tetani toxoid / Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus
International non-proprietary name (INN) or common name
equine influenza (live recombinant) and tetanus vaccine
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein

Product information

31/03/2021 ProteqFlu-Te - EMEA/V/C/000074 - II/0030/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for equidae

  • Live viral and inactivated bacterial vaccines
  • equine influenza virus + clostridium

Therapeutic indication

Active immunisation of horses of four months of age or older against equine influenza to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality.

Assessment history


How useful was this page?

Add your rating